Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
F2 Bioscience IV L.P.
   2. Issuer Name and Ticker or Trading Symbol
Radius Health, Inc. [RDUS] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
UGLAND HOUSE, SOUTH CHURCH STREET, PO BOX 309		 3. Date of Earliest Transaction (Month/Day/Year)
01/16/2015
(Street)

GEORGE TOWN, E9 KY1-1104		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/16/2015   J   1,794,983 (1) D (1) 0 D (2)  
Common Stock 01/16/2015   J   871,851 (3) D (3) 0 I By Fund (4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock Warrant $ 2.694 01/16/2015   J     249,932 (1) 02/14/2014 02/14/2019 Common Stock 249,932 (1) $ 0 0 D (2)  
Common Stock Warrant $ 2.694 01/16/2015   J     121,396 (3) 02/14/2014 02/14/2019 Common Stock 121,396 (3) $ 0 0 I By Fund (4)

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
F2 Bioscience IV L.P.
UGLAND HOUSE, SOUTH CHURCH STREET
PO BOX 309
GEORGE TOWN, E9 KY1-1104		     X    
F2 Bioscience IV GP Ltd.
UGLAND HOUSE, SOUTH CHURCH STREET
PO BOX 309
GEORGE TOWN, E9 KY1-1104		     X    
F2 Capital Ltd
PO BOX 3175 ROAD TOWN
TORTOLA, D8 VG 1110		     X    
Priestley Katherine
UGLAND HOUSE, SOUTH CHURCH STREET
PO BOX 309
GEORGE TOWN, E9 KY1-1104		     X    
F2 Bio Ventures V L.P.
KINGSTON CHAMBERS
P.O. BOX 173
ROAD TOWN, TORTOLA, D8 VG 1110		     X    
F2 Bio Ventures GP Ltd.
KINGSTON CHAMBERS
P.O. BOX 173
ROAD TOWN, TORTOLA, D8 VG 1110		     X    
Globeways Holdings Ltd
3RD FLOOR, GENEVE PLACE
WATERFRONT DRIVE, PO BOX 3175
ROAD TOWN, TORTOLA, D8 00000		     X    

Signatures

 /s/ Morag Law, attorney-in-fact for F2 Bioscience IV, L.P.   01/16/2015
**Signature of Reporting Person Date
 /s/ Morag Law, attorney-in-fact for F2 Bioscience IV GP Ltd.   01/16/2015
**Signature of Reporting Person Date
 /s/ Morag Law, attorney-in-fact for F2 Capital Limited   01/16/2015
**Signature of Reporting Person Date
 /s/ Morag Law, attorney-in-fact for Katherine Priestley   01/16/2015
**Signature of Reporting Person Date
 /s/ Morag Law, attorney-in-fact for F2 Bio Ventures V, L.P.   01/16/2015
**Signature of Reporting Person Date
 /s/ Morag Law, attorney-in-fact for F2 Bio Ventures GP Ltd.   01/16/2015
**Signature of Reporting Person Date
 /s/ Morag Law, attorney-in-fact for Globeways Holdings Ltd.   01/16/2015
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Reflects a liquidating pro rata distribution by F2 Bioscience IV L.P. ("F2 IV") to its limited and general partners.
(2) The reported securities are owned directly by F2 IV. F2 Bioscience IV GP Ltd. ("F2 IV GP") is the General Partner of F2 IV. Katherine Priestley and Globeways Holdings Limited ("Globeways") are members of F2 IV GP. F2 Capital Limited ("F2 Capital") is an investment adviser to F2 IV. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
(3) Reflects a liquidating pro rata distribution by F2 Bio Ventures V L.P. ("F2 Bio") to its limited and general partners.
(4) The reported securities are owned directly by F2 Bio. F2 Bio Ventures GP Ltd. is the General Partner of F2 Bio. Globeways is the sole member of F2 Bio Ventures GP Ltd. F2 Capital is an investment adviser to F2 Bio. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.